Literature DB >> 30692855

Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions.

Bedile İrem Tiftikçioğlu1.   

Abstract

It is important to assess the clinical outcome in patients with multiple sclerosis (MS) both during individual clinical follow-up and in clinical trials. The National MS Society's Clinical Outcomes Assessment Task Force has developed and recommended a multidimensional clinical outcome measure, namely Multiple Sclerosis Functional Composite (MSFC). This enables to measure the impact of MS in three key clinical dimensions: leg function and ambulation, arm and hand function, and cognitive function. Raw scores in different measurement scales are transformed into standard comparable scores (z-scores) and an overall composite score is calculated. In this review, the rationale behind the MSFC, administration and calculation of the composite score is discussed in detail.

Entities:  

Keywords:  MSFC; clinical outcome measure; multiple sclerosis; multiple sclerosis functional composite

Year:  2018        PMID: 30692855      PMCID: PMC6278631          DOI: 10.29399/npa.23330

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  3 in total

Review 1.  The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

Authors:  J S Fischer; R A Rudick; G R Cutter; S C Reingold
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

2.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

Review 3.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

  3 in total
  3 in total

Review 1.  Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

Authors:  Arielle Kasindi; Dieu-Trang Fuchs; Yosef Koronyo; Altan Rentsendorj; Keith L Black; Maya Koronyo-Hamaoui
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

2.  A Comparison of Magnetic Resonance Imaging Methods to Assess Multiple Sclerosis Lesions: Implications for Patient Characterization and Clinical Trial Design.

Authors:  Ewart Mark Haacke; Evanthia Bernitsas; Karthik Subramanian; David Utriainen; Vinay Kumar Palutla; Kiran Yerramsetty; Prashanth Kumar; Sean K Sethi; Yongsheng Chen; Zahid Latif; Pavan Jella; Sara Gharabaghi; Ying Wang; Xiaomeng Zhang; Robert A Comley; John Beaver; Yanping Luo
Journal:  Diagnostics (Basel)       Date:  2021-12-30

3.  A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data.

Authors:  Izumi Kawachi; Hiromichi Otaka; Kosuke Iwasaki; Tomomi Takeshima; Kengo Ueda
Journal:  Neurol Ther       Date:  2022-01-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.